In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $467.35, marking a +1.35% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.55% for the ...

Is there anything you wouldn't do for a loved one if they were dying? That's a morbid question, for sure, but the dilemma at the center of Some Bright Nowhere, Ann Packer's new novel, makes a reader ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

Discover What’s Streaming On: There’s a 2023 thriller movie, Some Other Woman, that recently began streaming on Netflix and has subscribers extremely confused. If that’s you, then you’ve come to the ...

Vertex Pharmaceuticals Incorporated is downgraded from Buy to Hold due to mounting headwinds and pipeline uncertainties. Vertex faces pressure from potential U.S. drug pricing reforms and tariffs, ...

Your genes code for all your traits. Some genes are dominant and expressed if you receive a copy from one parent. Others are recessive and only apparent if you receive a copy from both parents. Genes ...

CEO Sam Altman called a strange graph in its GPT-5 presentation a ‘mega chart screwup.’ CEO Sam Altman called a strange graph in its GPT-5 presentation a ‘mega chart screwup.’ is a senior reporter ...

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...